scholarly journals Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma

2018 ◽  
Vol 19 (10) ◽  
pp. 3014 ◽  
Author(s):  
Gianluca Lopez ◽  
Francesca Boggio ◽  
Stefano Ferrero ◽  
Nicola Fusco ◽  
Alessandro Del Gobbo
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Colorectal Carcinoma ◽  
Liver Metastases ◽  
Predictive Biomarkers ◽  
Treatment Modalities ◽  
Multiple Treatment ◽  
The Past ◽  
Immunohistochemical Markers ◽  
Current State

Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization.

scholarly journals Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Omar Abdel-Rahman ◽  
Winson Y. Cheung
Keyword(s):  
Liver Metastases ◽  
Management Strategy ◽  
Multimodality Treatment ◽  
Treatment Modalities ◽  
Considerable Proportion ◽  
Optimal Management ◽  
Related Factors ◽  
Multiple Treatment ◽  
Current Review ◽  
Systemic Therapies

Colorectal carcinoma (CRC) is one of the most common cancers worldwide. A considerable proportion of CRC patients may present with metastatic disease either at upfront presentation (synchronous with the primary) or following diagnosis and treatment of the primary tumor (metachronous). Management of CRC liver metastases is a challenging endeavor which frequently necessitates proper assessment of patient- and disease-related factors. There is an opportunity within the management of CRC liver metastases to incorporate multiple treatment modalities (including surgery, other locoregional treatments, and systemic therapy). The current review aims to provide an updated overview on the optimal management strategy for CRC patients with liver metastases with a specific focus on the integration of systemic and/or locoregional treatments among patients with resectable or potentially resectable disease.

scholarly journals FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION

2015 ◽  
Vol 28 (4) ◽  
pp. 222-230 ◽  
Author(s):  
Felipe José Fernandez COIMBRA ◽  
Heber Salvador de Castro RIBEIRO ◽  
Márcio Carmona MARQUES ◽  
Paulo HERMAN ◽  
Rubens CHOJNIAK ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Multimodal Treatment ◽  
Colorectal Liver Metastases ◽  
Epidemiological Data ◽  
Treatment Modalities ◽  
Established Method ◽  
Curative Intent ◽  
Pre Treatment ◽  
Definition Of

Background : Liver metastases of colorectal cancer are frequent and potentially fatal event in the evolution of patients with these tumors. Aim : In this module, was contextualized the clinical situations and parameterized epidemiological data and results of the various treatment modalities established. Method: Was realized deep discussion on detecting and staging metastatic colorectal cancer, as well as employment of imaging methods in the evaluation of response to instituted systemic therapy. Results : The next step was based on the definition of which patients would have their metastases considered resectable and how to expand the amount of patients elegible for modalities with curative intent. Conclusion : Were presented clinical, pathological and molecular prognostic factors, validated to be taken into account in clinical practice.

scholarly journals Molecular Targets for the Treatment of Metastatic Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2350
Author(s):  
Romain Cohen ◽  
Thomas Pudlarz ◽  
Jean-François Delattre ◽  
Raphaël Colle ◽  
Thierry André
Keyword(s):  
Colorectal Cancer ◽  
Molecular Targets ◽  
Predictive Biomarkers ◽  
Therapeutic Strategies ◽  
Her2 Amplification ◽  
Liquid Biopsies ◽  
Braf Mutations ◽  
Genetic Characteristics ◽  
New Developments ◽  
The Past

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTRK fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, HER2, NTRK).

Abstract 2997: Vessel co-option in colorectal cancer liver metastases mediates resistance to VEGF-targeted therapy

2014 ◽  
Author(s):  
Sophia Frentzas ◽  
Victoria L. Thompson ◽  
Peter B. Vermeulen ◽  
Shane Foo ◽  
Gina Brown ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases

Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer

2011 ◽  
Vol 47 (3) ◽  
pp. 340-355 ◽  
Author(s):  
Niels Frank Jensen ◽  
David Hersi Smith ◽  
Sune Boris Nygård ◽  
Maria Unni Rømer ◽  
Kirsten Vang Nielsen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Metastatic Colorectal Cancer ◽  
Predictive Biomarkers ◽  
Conventional Chemotherapy

scholarly journals Radiomics predicts response of individual HER2 ‐amplified colorectal cancer liver metastases in patients treated with HER2 ‐targeted therapy

2020 ◽  
Vol 147 (11) ◽  
pp. 3215-3223
Author(s):  
Valentina Giannini ◽  
Samanta Rosati ◽  
Arianna Defeudis ◽  
Gabriella Balestra ◽  
Lorenzo Vassallo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases

Colon Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 468 ◽  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Recurrent Disease ◽  
The United States ◽  
Treatment Modalities ◽  
Men And Women ◽  
Nccn Guidelines ◽  
The Third ◽  
The Past ◽  
Recent Version

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States, and in 2005, an estimated 104,950 new cases of colon cancer will occur. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. The NCCN guidelines summarize the management of colon cancer, from disease presentation through management of recurrent disease and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

Sign in / Sign up

Export Citation Format

Share Document